Canaccord lowered the firm’s price target on TransMedics (TMDX) to $109 from $169 and keeps a Buy rating on the shares. The firm noted its results missed expectations as the revenue shortfall was pinned on underlying volume in the US transplant market being more seasonally soft than expected, with the company’s quarter-over-quarter volume declines reflecting those of the entire market.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: